Cargando…

Ipilimumab administration for advanced melanoma in patients with pre-existing Hepatitis B or C infection: a multicenter, retrospective case series

Ipilimumab is a fully human, monoclonal antibody directed against Cytotoxic T Lymphocyte Antigen-4 (CTLA-4) that has demonstrated a survival benefit and durable disease control in patients with advanced melanoma. Ipilimumab is associated with potentially serious immune-related adverse events, includ...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ravi, Sowmya, Spencer, Kristen, Ruisi, Mary, Ibrahim, Nageatte, Luke, Jason J, Thompson, John A, Shirai, Keisuke, Lawson, David, Bartell, Heddy, Kudchadkar, Ragini, Gunter, Ngoc Thi, Mehnert, Janice M, Lipson, Evan J
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4195895/ https://www.ncbi.nlm.nih.gov/pubmed/25317333 http://dx.doi.org/10.1186/s40425-014-0033-1

Ejemplares similares

Immuno-oncology safety education experience: Key lessons from ipilimumab (IPI)
por: Bartell, Heddy, et al.
Publicado: (2015)

A phase IB study of ipilimumab with peginterferon alfa-2b in patients with unresectable melanoma
por: Brohl, Andrew S., et al.
Publicado: (2016)

Patterns of response with talimogene laherparepvec in combination with ipilimumab or ipilimumab alone in metastatic unresectable melanoma
por: Chesney, Jason, et al.
Publicado: (2019)

Survival of melanoma patients with brain metastases treated with ipilimumab and stereotactic radiosurgery
por: Tazi, Karim, et al.
Publicado: (2015)

A Patient with HIV Treated with Ipilimumab and Stereotactic Radiosurgery for Melanoma Metastases to the Brain
por: Ruzevick, Jacob, et al.
Publicado: (2013)

Safety and efficacy of ipilimumab to treat advanced melanoma in the setting of liver transplantation
por: Morales, Rita E, et al.
Publicado: (2015)

Colonic ulcerations may predict steroid-refractory course in patients with ipilimumab-mediated enterocolitis
por: Jain, Animesh, et al.
Publicado: (2017)

GIFT4-augmented B cells for melanoma immunotherapy
por: Deng, Jiusheng, et al.
Publicado: (2014)

Talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone for advanced melanoma: 5-year final analysis of a multicenter, randomized, open-label, phase II trial
por: Chesney, Jason A, et al.
Publicado: (2023)

High-Dose Ipilimumab and High-Dose Interleukin-2 for Patients With Advanced Melanoma
por: Silk, Ann W., et al.
Publicado: (2020)

Ipilimumab
Publicado: (2012)

Phase II clinical and immune correlate study of adjuvant nivolumab plus ipilimumab for high-risk resected melanoma
por: Khushalani, Nikhil I, et al.
Publicado: (2022)

Ipilimumab Pharmacotherapy in Patients with Metastatic Melanoma
por: Jeter, Joanne M., et al.
Publicado: (2012)

Balancing Inflammation: The Link between Th17 and Regulatory T Cells
por: Diller, Maggie L., et al.
Publicado: (2016)

Healthcare cost comparison analysis of nivolumab in combination with ipilimumab versus nivolumab monotherapy and ipilimumab monotherapy in advanced melanoma
por: Potluri, Ravi, et al.
Publicado: (2019)

Eosinophilic airway inflammation and eosinophilic chronic rhinosinusitis during nivolumab and ipilimumab
por: Watanabe, Hirofumi, et al.
Publicado: (2020)

Combination anti-PD1 and ipilimumab therapy in patients with advanced melanoma and pre-existing autoimmune disorders
por: Brown, Lauren J, et al.
Publicado: (2021)

Inflammatory demyelinating polyneuropathy versus leptomeningeal disease following Ipilimumab
por: Cafuir, Lorraine, et al.
Publicado: (2018)

Safety and efficacy of the combination of nivolumab plus ipilimumab in patients with melanoma and asymptomatic or symptomatic brain metastases (CheckMate 204)
por: Tawbi, Hussein A, et al.
Publicado: (2021)

When Benign Tumors Mimic Malignancies: A Case of Lymphangiomatosis Masquerading as Metastatic Disease
por: Spencer, Kristen R., et al.
Publicado: (2013)

Safety and efficacy of combination nivolumab plus ipilimumab in patients with advanced melanoma: results from a North American expanded access program (CheckMate 218)
por: Hodi, F. Stephen, et al.
Publicado: (2020)

Ipilimumab: Melanoma and beyond
por: Patel, Vishal, et al.
Publicado: (2011)

Pre-existing immune status associated with response to combination of sipuleucel-T and ipilimumab in patients with metastatic castration-resistant prostate cancer
por: Sinha, Meenal, et al.
Publicado: (2021)

Risks and benefits of reinduction ipilimumab/nivolumab in melanoma patients previously treated with ipilimumab/nivolumab
por: Chapman, Paul B, et al.
Publicado: (2021)

Adverse events induced by nivolumab and ipilimumab combination regimens
por: Somekawa, Kohei, et al.
Publicado: (2022)

Pembrolizumab-induced lichen planus pemphigoides in a patient with metastatic Merkel cell carcinoma
por: Kwon, Chase W., et al.
Publicado: (2020)

Use of ipilimumab in the treatment of melanoma
por: Acharya, Utkarsh H, et al.
Publicado: (2013)

Ipilimumab-induced colonic perforation
por: Burdine, Lyle, et al.
Publicado: (2014)

Ipilimumab-Induced Neutropenia in Melanoma
por: Ban-Hoefen, Makiko, et al.
Publicado: (2016)

Ipilimumab induced digital vasculitis
por: Padda, Amrita, et al.
Publicado: (2018)

Long-term real-world experience with ipilimumab and non-ipilimumab therapies in advanced melanoma: the IMAGE study
por: Dalle, Stéphane, et al.
Publicado: (2021)

Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma
por: Wolchok, Jedd D., et al.
Publicado: (2022)

A Case of Vogt-Koyanagi-Harada Disease-Like Uveitis Induced by Nivolumab and Ipilimumab Combination Therapy
por: Minami, Keisuke, et al.
Publicado: (2021)

Ipilimumab in patients with melanoma and autoimmune disease
por: Kyi, Chrisann, et al.
Publicado: (2014)

Infectious Colitis Associated With Ipilimumab Therapy
por: McCutcheon, Jessica L., et al.
Publicado: (2014)

Ipilimumab: A tale of twists and turns
por: Abhyankar, Dhiraj
Publicado: (2018)

Ipilimumab (Immune Checkpoint Inhibitors) Hypophysitis
por: Stagnetto, Margot, et al.
Publicado: (2020)

Automatic discovery of image-based signatures for ipilimumab response prediction in malignant melanoma
por: Harder, Nathalie, et al.
Publicado: (2019)

Existing data sources for clinical epidemiology: The Danish Knee Arthroplasty Register
por: Pedersen, Alma B, et al.
Publicado: (2012)

Trough levels of ipilimumab in serum as a potential biomarker of clinical outcomes for patients with advanced melanoma after treatment with ipilimumab
por: Koguchi, Yoshinobu, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_6f6ft8p92s2hfjmuosir4vqefd